Loading...
Market
What will be the main reason for Enteromix distribution delay by June 30, 2025?
2
Russia•Ministry of Health•Enteromix•Radiology Medical Research Center•Russian Ministry of Health•Andrey Kaprin•Alexander Gintsburg
Resolution / Starting Odds
Manufacturing issues • 25%
Regulatory hurdles • 25%
Supply chain disruptions • 25%
Other • 25%
Reports from the Russian Ministry of Health or reputable news outlets
Story
Russia to Launch Free Enteromix Cancer Vaccine Using mRNA Technology in 2025, Aiming for 75-80% Tumor Reduction
Dec 17, 2024, 10:01 PM
Russia's Ministry of Health has announced the development of a personalized cancer vaccine, named Enteromix, which is set to be distributed free of charge to patients starting in early 2025. The vaccine, developed by the Radiology Medical Research Center of the Russian Ministry of Health, utilizes mRNA technology and is designed to treat cancer patients rather than prevent cancer in the general public. Andrey Kaprin, the General Director of the center, stated that the vaccine will be tailored to each patient's specific needs and is expected to reduce tumor size by 75-80%. The vaccine's development has been supported by preclinical trials showing its ability to suppress tumor growth and prevent cancer spread, according to Alexander Gintsburg, Director of the Gamaleya National Research Center for Epidemiology and Microbiology. The cost to the state for each dose is estimated at 300,000 rubles, but it will be provided free to citizens. Clinical trials for the vaccine are expected to begin in late 2024 or early 2025, focusing on patients aged 18 to 75 with histologically confirmed tumors who have exhausted all other treatment options.
View original story
Similar markets
Successful with expected results • 25%
Partially successful • 25%
Unsuccessful • 25%
Results inconclusive • 25%
Regulatory issues • 25%
Financial issues • 25%
Operational challenges • 25%
No delay • 25%
Less than 25% • 25%
25% to 50% • 25%
51% to 75% • 25%
More than 75% • 25%
Technical issues • 25%
Regulatory challenges • 25%
Market conditions • 25%
Other reasons • 25%
More than 10 countries • 25%
None • 25%
1 to 5 countries • 25%
6 to 10 countries • 25%
Breast Cancer • 25%
Lung Cancer • 25%
Colorectal Cancer • 25%
Other • 25%
Environmental concerns • 25%
Legal challenges • 25%
Administrative issues • 25%
Other • 25%
Regulatory issues • 25%
Supply chain issues • 25%
Funding issues • 25%
Other • 25%
Less than 5 billion rubles • 25%
5 to 10 billion rubles • 25%
10 to 20 billion rubles • 25%
More than 20 billion rubles • 25%